HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF divestiture

This article was originally published in The Rose Sheet

Executive Summary

Flavors and fragrances supplier sells Oregon fruit and vegetable concentrate business to Salem-based Kerr Concentrates in a transaction that closed June 7, International Flavors & Fragrances announces. With annual sales of approximately $23 mil., fruit and vegetable business employs 35 people, according to IFF. Divestiture is in line with IFF reorganization efforts focused on growth of core flavors and fragrances businesses, firm adds. Move follows recent sale of IFF's Brazilian fruit preparations business and a portion of the aroma chemicals business acquired with Bush Boake Allen (1"The Rose Sheet" Feb. 4, 2002, p. 7)...

You may also be interested in...



IFF R&D “Key Initiative” To Drive Growth In 2002

International Flavors & Fragrances will boost investment in research & development by $10 mil.-$12 mil. over the next few years in an effort to drive top-line growth, the fragrance supplier said

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel